From Cells to Strands: A Systematic Review Comparing Exosome Therapy, Platelet-Rich Plasma, and Minoxidil for Androgenetic Alopecia Treatment

In this phase I/II clinical trial, placenta-derived mesenchymal stem cell exosome therapy significantly improved hair density and diameter, and reduced hair loss in patients with androgenetic alopecia, though further large-scale studies are needed to confirm these results and investigate the underlying molecular mechanisms.

In this multicenter observational study, researchers found that using micrografts with human follicle mesenchymal stem cells increased hair density significantly in both male and female patients with mild to moderate androgenic alopecia after 12 months, suggesting a viable alternative for hair regrowth.

This randomized control trial reported that mesenchymal stem cell-derived exosomes significantly increased hair density and thickness in patients with androgenic alopecia, with a mean increase of 35 hairs/cm² over 12 weeks compared to the placebo group, which showed minimal hair density changes.

In this study, injecting foreskin-derived mesenchymal stromal cell exosomes into the scalps of men with androgenetic alopecia significantly increased hair density and patient satisfaction without side effects over a 12-week period.

This study found that treating patients with androgenetic alopecia using exosomes from adipose tissue stem cells over 24 weeks significantly increased hair density and patient satisfaction without severe adverse effects, suggesting a promising alternative treatment for hair loss.

This abstract introduces "Dermis," an open-access, peer-reviewed journal focused on dermatology, which publishes significant new research in the field of dermatology. Specific research results are not included here.

This study found that platelet-rich plasma therapy may be a useful alternative to 5% topical minoxidil for treating androgenetic alopecia, with differences in the effectiveness and patient satisfaction outcomes observed.

In this study, researchers found that platelet-rich plasma therapy demonstrated significantly higher efficacy than topical minoxidil for treating androgenetic alopecia in a Pakistani population, with a 91.7% negative hair pull rate compared to 69.4% for minoxidil after 12 weeks.

This study concluded that, in male patients with mild-to-moderate androgenetic alopecia, injections of PRP prepared by an automated method combined with topical 5% minoxidil were effective and safe, showing superior clinical efficacy and patient satisfaction compared to PRP alone.

In this study, PRP therapy did not show significant effectiveness in treating androgenetic alopecia in patients over a 6-month period, with 45% of participants reporting no improvement in hair growth, although adverse effects were minimal and non-serious.

This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.

In this study, both platelet-rich plasma and minoxidil increased hair counts and density in moderate androgenetic alopecia in men, but patient satisfaction was higher with minoxidil, which also had fewer side effects.

In this study, activated platelet-rich plasma improved hair density and thickness in patients with androgenetic alopecia, with higher platelet counts enhancing these effects over time.

This study found that topical cetirizine increased hair shaft thickness and improved clinical outcomes from the patients' perspective in female androgenetic alopecia compared to minoxidil alone, with similar side effect profiles.

This review examines the definition, classification, mechanism, clinical efficacy for hair regrowth, and potential adverse effects of platelet rich plasma, but does not present new experimental results.

This study found that androgenetic alopecia is significantly associated with moderate impairment of health-related quality of life and emotions, but not with depressive symptoms.

This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.

Exosomes from stem cells might help treat hair loss.

This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.

This study found that combining platelet-rich plasma therapy with minoxidil was more effective in treating androgenetic alopecia in men than either treatment alone.

In this study, PRP increased hair density in areas treated for androgenetic alopecia, but there was no significant difference when compared to placebo-treated areas.

This study found that PRP injections using the Eclipse system significantly improved hair density and caliber in women with androgenetic alopecia compared to saline placebo at 24 weeks.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

This study suggests platelet-rich plasma may be more effective than other non-surgical treatments for male androgenetic alopecia, while low-level laser therapy ranks highest for women; however, the evidence quality was low.

The authors concluded that platelet-rich plasma (PRP) shows promising potential as a safe treatment for hair restoration in androgenic alopecia, though further research is needed to refine its use and confirm long-term effects.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This study found that platelet-rich plasma combined with topical minoxidil was more effective in increasing hair density for male-type baldness than either treatment alone.

This study found that platelet-rich plasma was effective for hair regrowth in women with androgenic alopecia, though less so than minoxidil, but it was associated with improved quality of life responses.

This study found that combining stromal vascular fraction with PRP injections significantly improved hair density and reduced hair loss more effectively than PRP alone in patients with androgenetic alopecia.

This study found that 5% topical minoxidil was moderately more effective at increasing hair regrowth than 10% minoxidil and placebo in men with androgenetic alopecia.

This study's meta-analysis reported that PRP injections significantly increased hair density compared to baseline and placebo in androgenetic alopecia patients, supporting its use as a beneficial treatment.

This study found that platelet-rich plasma may effectively increase hair follicle numbers in men with androgenetic alopecia, but changes in hair thickness plateaued after the second injection.

This study found that platelet-rich plasma significantly increased hair count, density, and the percentage of anagen hairs in patients with androgenetic alopecia, but these improvements did not correlate with platelet or growth factor levels.

In this study, subdermal platelet-rich plasma injections significantly increased hair count and shaft caliber in individuals with androgenetic alopecia, with monthly treatments potentially offering greater benefits.

This study found that the new minoxidil formulation, DC0120, was noninferior to the marketed product ALOSTIL® in promoting hair growth for men with androgenetic alopecia over 16 weeks.

This review discusses the diverse applications of platelet-rich plasma in aesthetic dermatology and assesses the existing literature on its effectiveness, reporting no new clinical results.

This study found that platelet-rich plasma injections significantly improved hair density, thickness, and patient satisfaction in women with female pattern hair loss compared to a placebo.

This study found that platelet-rich plasma was more effective for treating alopecia areata than topical 5% minoxidil, leading to earlier hair regrowth and reduction in hair abnormalities.

This study found that platelet-rich plasma did not significantly improve hair mass index or hair count in women with female androgenetic alopecia, though some patients perceived benefits in hair quality.

This study found that platelet-rich plasma was not effective in treating androgenetic alopecia in men with grade 4–6 hair loss.

This study found that platelet-rich plasma significantly increased hair density and anagen hair proportions in androgenetic alopecia patients, suggesting potential as an adjuvant therapy.

This study found that platelet-rich plasma injections significantly increased hair count and density in patients with male pattern hair loss without major side effects, suggesting it may be a safe and effective treatment option.

In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.

This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.